Nathan Fowler, MD and Anas Younes, MD
In this segment, “Moving Novel Therapies to Frontline for DLBCL”, Nathan Fowler, MD and Anas Younes, MD discuss prospects for CAR-T cells and novel combinations as upfront therapy for diffuse large B-cell lymphoma (DLBCL).
Ibrutinib, lenalidomide, and venetoclax have activity in relapsed/refractory DLBCL. Currently, strategies to use these therapies earlier are being studied, including with first line R-CHOP. If successful, a better understanding of the biology of DLBCL will be crucial to tailor treatment for selected patients.